Eloxx Pharmaceuticals Highlights Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Positive Phase 2 Results for ELX-02

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, recently held a key opinion leader (KOL) event to discuss the significant unmet medical needs of patients with Alport syndrome. The event featured two renowned experts in Alport syndrome: Professor Detlef Bockenhauer and Professor Rachel Lennon. Alport syndrome is a rare progressive hereditary glomerul..